// App-Quantinova.ai

OP0253 : AUTOANTIBODY STATUS IN DERMATOMYOSITIS AND POLYMYOSITIS PATIENTS DEFINES BOTH CANCER RISK AND SURVIVAL WITH ANA NEGATIVITY IN CASES WITH CONCOMITANT CANCER HAVING A WORSE SURVIVAL

Researchers

Presenter

  • A. Watad

Principal Investigators

  • D. Mcgonagle

  • M. Lidar

  • N. L. Bragazzi

  • D. Comanesther

  • A. Cohen

  • H. Amital

Medical Centers

  • Sheba Medical Center, Department of Medicine B’, Rheumatology Unit, Ramat Gan, Israel

  • NIHR - Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom

  • Chaim Sheba Academic Medical Center, Pathology, Ramat Gan, Israel

  • University of Genoa, Genoa, Italy

  • Clalit Health Services, Tel Aviv, Israel

Locations

  • Israel

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Juvenile dermatomyositis

  • juvenile polymyositis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Janssen Research & Development

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved